Association between Genetic Variants in Pre-microRNAs and Survival of Early Stage Non-small Cell Lung Cancer
분야
의약학 > 내과학
저자
이용훈 , ( Mi Jeong Hong ) , ( Shin Yup Lee ) , ( Seung Soo Yoo ) , ( Jae Hee Lee ) , ( Seung Ick Cha ) , ( Chang Ho Kim ) , ( Eung Bae Lee ) , ( Hyo Sung Jeon ) , ( Ji Woong Son ) , ( Jae Yong Park )
발행기관
대한결핵 및 호흡기학회
간행물정보
대한결핵및호흡기학회 추계학술발표초록집 2012년, 제114권 147(총1페이지)
파일형식
0y909801.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    1,000원
    적립금
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    영문초록
    Introduction: Altered miRNA expression plays an important role in the initiation and progression of lung cancer. Single nucleotide polymorphisms (SNPs) in pre-miRNAs could alter miRNAs processing, or expression, and hence, could influence the prognosis of lung cancer. We evaluated the effects of four SNPs in pre-miRNAs (pre-miR-146a rs2910164, pre-miR-149 rs2292832, pre-miR-196a rs11614913, and pre-miR-499 rs3746444) on the survival outcomes in early-stage NSCLC. Methods: Surgically resected 363 NSCLC patients were enrolled. The four SNPs were genotyped using a PCR-RFLP assay. The genotype associations with overall survival (OS) and disease free survival (DFS) were analyzed. Results: The pre-miR-149 rs2292832T>C and pre-miR-196a rs11614913C>T were found to be significantly associated with OS and DFS. The rs2292832 TC or CC genotype exhibited a significantly better OS and DFS compared to the rs2292832 TT genotype (adjusted hazard ratio [aHR] for OS=0.66, p=0.01; and aHR for DFS=0.64, p=0.004). For the pre-miR-196a rs11614913C>T, patients with the CT or TT genotype had a significantly better OS and DFS than those with the CC genotype (aHR for OS=0.70, p=0.05; and aHR for DFS=0.66, p=0.01). When the two SNPs were combined, OS and DFS improved in a dose-dependent manner as the number of good genotypes increased (p=0.002; p=0.0001). Conclusions: These results suggest that miR-149 and miR-196a may be involved in the pathogenesis of NSCLC and that rs2292832 and rs11614913 can be used as prognostic markers for patients with surgically-resected early stage NSCLC.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.